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http://genomemedicine.com/content/6/5/43RESEARCH Open AccessGenome-wide mutational landscape of mucinous
carcinomatosis peritonei of appendiceal origin
Hakan Alakus1,10, Michele L Babicky2, Pradipta Ghosh3,5, Shawn Yost4, Kristen Jepsen1, Yang Dai1, Angelo Arias1,
Michael L Samuels9, Evangeline S Mose2, Richard B Schwab3,5, Michael R Peterson6, Andrew M Lowy2,5†,
Kelly A Frazer1,5,7,8*† and Olivier Harismendy1,5,7†Abstract
Background: Mucinous neoplasms of the appendix (MNA) are rare tumors which may progress from benign to
malignant disease with an aggressive biological behavior. MNA is often diagnosed after metastasis to the peritoneal
surfaces resulting in mucinous carcinomatosis peritonei (MCP). Genetic alterations in MNA are poorly characterized
due to its low incidence, the hypo-cellularity of MCPs, and a lack of relevant pre-clinical models. As such, application
of targeted therapies to this disease is limited to those developed for colorectal cancer and not based on molecular
rationale.
Methods: We sequenced the whole exomes of 10 MCPs of appendiceal origin to identify genome-wide somatic
mutations and copy number aberrations and validated significant findings in 19 additional cases.
Results: Our study demonstrates that MNA has a different molecular makeup than colorectal cancer. Most tumors
have co-existing oncogenic mutations in KRAS (26/29) and GNAS (20/29) and are characterized by downstream PKA
activation. High-grade tumors are GNAS wild-type (5/6), suggesting they do not progress from low-grade tumors.
MNAs do share some genetic alterations with colorectal cancer including gain of 1q (5/10), Wnt, and TGFβ pathway
alterations. In contrast, mutations in TP53 (1/10) and APC (0/10), common in colorectal cancer, are rare in MNA.
Concurrent activation of the KRAS and GNAS mediated signaling pathways appears to be shared with pancreatic
intraductal papillary mucinous neoplasm.
Conclusions: MNA genome-wide mutational analysis reveals genetic alterations distinct from colorectal cancer,
in support of its unique pathophysiology and suggests new targeted therapeutic opportunities.Background
Mucinous neoplasms of the appendix (MNA), though
rare, represent a common subtype of appendiceal tu-
mors with an incidence of one per million in the US [1].
Primary MNAs are classified histologically as either low-
grade appendiceal mucinous neoplasm (LAMN) showing
no classic infiltrative invasion or mucinous adenocarcinoma
[2] which reflects a high-grade, invasive form of the disease
associated with a worse prognosis. MNAs are often diag-
nosed after primary tumor rupture and metastasis to the* Correspondence: kafrazer@ucsd.edu
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unless otherwise stated.peritoneal cavity and designated as high or low histological
grade. The metastatic tumor cells often secrete large
quantities of extracellular mucin resulting in the clin-
ical syndrome known as mucinous carcinomatosis
peritonei (MCP) or pseudomyxoma peritonei (PMP).
Due to its location in the peritoneal cavity, the organ
of origin of MCP has been debated for a long time [3],
but a more systematic histology assessment [4] as well
as molecular characterization [5] has concluded that
the vast majority of MCP originates from the appendix.
Once peritoneal metastasis has occurred, disease progres-
sion, though relatively indolent, is frequently fatal [2,6].
The primary treatment of low-grade MCP is surgical.
Patients with high-grade MCP and those with inoperable
disease typically receive therapies approved for colorectal
cancer (CRC), although there is a limited understanding of
their efficacy. Furthermore, the genome-wide mutationalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tionship to CRC has not been thoroughly studied. As a
consequence, targeted therapies, which have dramatically
improved the outcome in many cancer types, including
CRC, have not yet impacted MNA treatment. A few fo-
cused studies of MNAs have reported activated KRAS in
50% to 100% of the cases [5,7-10], loss of heterozygosity of
APC in one patient [11,12], and p53 over-expression in
44% of the cases [10]. A recent study identified frequent
mutations in GNAS in LAMN, which were associated with
high mucin production [13]. However, the molecular study
of MNA remains technically challenging due to: (1) its very
low incidence; (2) the poor quality of available MCP
samples which have low cellularity (often <5%) and an
abundance of extracellular mucin; and (3) the absence
of relevant preclinical model systems such as cell lines
or xenografts. Notably, none of the molecular alter-
ations identified so far have directly impacted patient
care and all resulted from candidate gene approaches.
Systematic genome-wide sequencing of many cancer
types has recently revealed an extensive repertoire of
cancer-driving genes and pathways. Such studies have
led to an increased understanding of tumor biology of-
fering new opportunities for therapy and prognosis.
Many cancers including CRC have been initially ex-
plored genome-wide by analyzing a small number of
samples [14], with findings later borne out by larger-
scale studies [15]. Here, we present the first compre-
hensive molecular profiling of MCP from appendiceal
origin, an advanced stage of MNA with limited treat-
ment options. We performed whole exome sequencing
of 10 cases, nine low-grade and one high-grade, and
validated the results in 19 additional cases including
three primary LAMN. Our findings have immediate
implications for clinical care and suggest opportunities
to develop novel therapies targeting pathways driving
both tumor growth and mucin production.Methods
Specimens
Research on specimen from human MNA was approved
by the Institutional Review Board of the University of
California, San Diego. Before enrolling in the study, all
patients gave informed consent. DNA was obtained
from matched blood (normal DNA) or fresh frozen
tumor tissue (tumor DNA) isolated by laser-capture
micro-dissection (LCM) of tumor cells from MCP of
appendiceal origin (nine low grade, one high grade
samples from the discovery group - Additional file 1:
Figure S1) or directly from the formalin fixed paraffin
embedded (FFPE) slides (five high-grade MCP, 11
low-grade MCP, and three LAMN samples from the
validation group).Sequencing
For the discovery group, we performed whole exome
capture on 2.5 μg of genomic DNA from 10 normal
samples or 500 ng of DNA from 10 matching LCM
tumor samples using the Agilent SureSelect Human
All Exon v4 capture kit. Each resulting library was se-
quenced using one-quarter of a lane of Illumina HiSeq
2000 for 2 × 100 cycles. The resulting reads were aligned
to the human genome with BWA, refined with GATK,
the somatic variants and copy numbers were called
using Varscan. The raw sequencing reads are available at
the NCBI short read archive (SRA067608). For the valid-
ation group, we detected the presence of low frequency
mutations using ultra deep targeted sequencing of PCR
amplicons from KRAS codons 12/13/146, GNAS codon
201/227, and SMAD2 codon 465 on the Illumina HiSeq
2000. We also confirmed the presence of KRAS and
GNAS mutations by digital droplet PCR assays specific
to KRAS G12A/V/D and GNAS R201C/H (RainDance
Technologies’ RainDrop dPCR system).
Immunohistochemistry
Adjacent slides from FFPE blocks were stained for H&E
or incubated with primary antibodies against Phospho-p44/
42 MAPK (Erk1/2) (Thr202/Tyr204) or Phospho-(Ser/Thr)
PKA Substrate (Cell Signaling Inc.). All staining was com-
pared to normal appendix. The signal was scored by stain-
ing intensity (0 to 3+) and fraction of stained tumor cells
(0% to 100%). The enzyme was considered active at a signal
greater than 2 in more than 25% of tumor cells.
Complete material and methods are available as
Supplemental Information (Additional file 2).
Results and discussion
Global mutational landscape
We identified 2,173 somatic mutations located in the se-
quenced regions across all 10 tumors (Additional file 3:
Table S1) with a median of 54 non-silent mutations per
tumor, a number similar to non-hypermutated colorectal
cancers (CRC) [15]. Not surprisingly, the high-grade
sample had the highest mutation rate (4.9 per Mbp).
The median allelic fraction observed at somatically
mutated positions was 0.43 (Additional file 1: Figure
S2). Therefore the laser-capture microdissection suc-
cessfully enriched for tumor cells up to 86%, ensuring
sensitive mutation identification. The profile of substi-
tutions showed a majority (55%) of C > T transitions, a
common characteristic of CRCs, which suggests that
similar mechanisms are involved in DNA mutagenesis
and repair (Additional file 3: Table S2).
Of the somatic mutations identified, 693 predicted an
altered protein sequence in 642 unique genes (Additional
file 3: Table S3 and S4) of which 36 are mutated in two or
more tumors. The altered genes significantly affected 20
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Table S5), most of which represent common signaling path-
ways mutated in cancer, overlapping with Ras-PI3K-Akt,
Wnt, TGFβ, or cAMP-PKA pathways. To determine the
significance of each recurrently mutated gene, we measured
their false recurrence rate (FRR) (Additional file 2). Of
the 36 recurrently mutated genes, 25 were considered
significant (FRR <0.05, Table 1). The non-significantTable 1 Genes recurrently mutated in MNA
Gene N. MNA mutated FRRa Fraction of sam
(MNA | CRCb)
KRAS 10 0 1 | 0.42
GNAS 9 0 0.9 | 0.06
POM121L12 2 0 0.2 | 0.02
DOK6 2 0 0.2 | 0.02
IRX6 2 0.001 0.2 | 0.02
KRT37 2 0.001 0.2 | 0.02
EEF1A1 2 0.003 0.2 | 0.01
CRY2 2 0.003 0.2 | 0.01
SMAD2 2 0.004 0.2 | 0.04
SNTG1 2 0.004 0.2 | 0.02
OCA2 2 0.007 0.2 | 0.03
EPHA10 2 0.007 0.2 | 0.02
ZNF512B 2 0.008 0.2 | 0.03
PTCHD3 2 0.009 0.2 | 0.04
ANKRD24 2 0.009 0.2 | 0.02
DCLK1 2 0.011 0.2 | 0.05
PCDH10 2 0.011 0.2 | 0.09
MTIF2 2 0.014 0.2 | 0.02
ITGA11 2 0.014 0.2 | 0.02
COL5A3 2 0.014 0.2 | 0.04
PCDH17 2 0.015 0.2 | 0.08
CNTNAP2 2 0.018 0.2 | 0.06
TRPS1 2 0.022 0.2 | 0.09
ABCA7 2 0.04 0.2 | 0.06
FAT4 3 0.045 0.3 | 0.2
DOCK3 2 0.061 NA
ZNF469 2 0.067 NA
SPTA1 2 0.068 NA
COL6A3 2 0.089 NA
LAMA1 2 0.105 NA
APOB 2 0.261 NA
CSMD1 2 0.305 NA
MUC16 2 0.659 NA
TTN 2 0.992 NA
aFalse recurrence rate (FRR) <0.05 are in bold.
bMutSig significant (P <0.01).genes contained expected false positives such as TTN and
MUC16 or CSMD1 [16], highlighting the specificity of the
FRR estimation. The significant genes included genes fre-
quently mutated in CRC such as KRAS (mutated in N= 10/
10), SMAD2 (2/10), and FAT4 (3/10), as well as genes mu-
tated in other cancers such as GNAS (9/10). Ten of the 25
remaining genes could be linked to oncogenesis, however
with a lesser degree of certainty. Surprisingly, the mostples mutated Link to oncogenesis
Cancer Gene Census: pancreatic, colorectal, lung
Cancer Gene Census: pituitary tumors
RET signaling
Homeobox TF neurogenesis
Proto-oncogene of PTI1: Prost. Tumor Inducing 1
TFGβ pathway
Receptor for EPH pathway
Homologous to PTCH1: Shh receptor
Intestinal tumor stem cell marker
Silenced in multiple epithelial cancers
Mutated and silenced in GI cancer
Tumor suppressor in Gliomas
GATA factor involved in EMT in breast cancer
Putative receptor of Hippo pathway
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not recurrently mutated in the 10 MNAs analyzed, suggest-
ing distinct oncogenic processes.
Using the differences in coverage depth between tumor
and normal DNA, as well as evidence of loss ofFigure 1 Genome-wide copy number analysis. The log2 ratio of covera
(black dots) along each chromosome arranged in linear order (alternate gre
as amplified (red) or deleted (blue). Loss of heterozygosity at germline SNV
nine panels correspond to low-grade MCPs and the bottom panel to high-heterozygosity, we were able to identify large (>1 Mb) copy
number aberrations (CNAs) (Figure 1). CNAs in the
low-grade MCPs represented a smaller portion of the
genome than for the high-grade MCP (median 138 Mb
vs. 1.1 Gb - Additional file 3: Table S6), suggesting age between tumor and normal is indicated for all targeted exons
y/white shade). The inferred segments larger than 1 Mb are indicated
s is indicated by a dark blue tick at the bottom of each panel. The top
grade MCP.
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An analysis at the level of the chromosome arm and
cytobands revealed several recurrent CNAs (Additional
file 3: Table S7 to S9) among which the gain of 1q
(amplified in N = 5 tumors), 20q (N = 2), 12p13 (N = 2),
and 19p12 (N = 3) as well as the loss of 1p36 (N = 3),
20p12 (N = 2), or 16q24 (N = 3). Gain of 1q, 20q or
12p13 as well as loss of 1q36 or 20p12 are also fre-
quent in CRC [15]. In contrast, CNAs present in more
than 50% of CRC tumors, such as amplification of
chromosomes 7, 8, or 13, loss of 8p or 18, were absent
or only seen once in MNA. Notably, none of the ampli-
fied large chromosomal segments showed a ploidy
higher than 4, and we identified only two focal dele-
tions and one focal amplification, spanning ST14, p15/
p16, and CCND1 genes, respectively, in three inde-
pendent samples (Additional file 3: Table S10). This
suggests that high and recurrent copy number aberra-
tions are uncommon and unlikely to drive MNA pro-
gression. Therefore both the sequencing and the copy
number analysis demonstrate that while MNAs mayFigure 2 The MNA mutational landscape. Samples from 19 MNA patien
somatic mutations (Additional file 3: Tables S4 and S11) (b) or copy numbe
sequencing using the discovery group (10 MCP samples - left side) or as va
(d) The levels of pErk, pAkt, and phosphorylated PKA substrates were meas
on signal strength and fraction of positive cells (Methods). (*) Only expecte
may impact the sensitivity of the validation.share some somatic mutations with CRC, there are
clear genetic differences between these cancer types.
GNAS and KRAS mutations in low-grade MCP
The most striking genetic alterations identified were the
presence of both GNAS and KRAS mutations in every
low-grade MCP. KRAS was mutated in all nine low-
grade MCP samples, with three different missense alter-
ations: G12V (N = 7), G12D (N = 1), and A146T (N = 1).
The analysis of 14 additional samples, including three
primary LAMN, by ultra-deep targeted sequencing re-
vealed that KRAS was mutated in 91% (21/23) of
low-grade MNAs (Figure 2 and Additional file 3: Table
S11a). This incidence is significantly higher than ob-
served in CRC [15] or in previous reports on MNA
[5,7-10,13]. The less frequent KRAS-A146T mutation
has been observed in approximately 5% of CRC [15] and
increases RAS activity, mediating resistance to EGFR in-
hibitor gefitinib [17]. Immunostaining of 14 specimens
(both low-grade MCP and LAMN), revealed frequent
phosphorylation of Erk and Akt (Figures 2 and 3) asts were assessed for histopathology and cellularity (a), analyzed for
r aberrations (Additionalfile 3: Tables S7-S9) (c) as identified by exome
lidated by digital PCR and deep sequencing (19 samples - right side).
ured by immunohistochemistry and determined to be positive based
d codons were investigated in the validation group. Low cellularity
Figure 3 Immunohistochemistry. Normal appendix epithelium (a-d), low-grade MCP (e-h), high-grade MCP (i-l) samples were stained using
H&E (a, e, i), anti-pErk staining (b, f, j), anti-pAkt staining (c, g, k), and Anti-phospho-PKA substrates (d, h, l) on matched adjacent sections.
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oncogenic KRAS mutations. Finally, we observe, in one
sample, the co-occurence of two KRAS mutations
(G12V and G12D - Additional file 3: Table S17), indicat-
ing that different populations of KRAS-mutated cells
can co-exist within one specimen, as previously observed
in CRC [18].
GNAS encodes for the stimulatory G protein alpha
subunit (Gαs). It was originally found to be mutated in
pituitary tumors [19] and more recently in intraductal
papillary mucinous neoplasms of the pancreas (IPMN),
gastric, and intestinal adenomas, as well as CRC and
low-grade mucinous neoplasm of the appendix (LAMN)
[13,20-23]. We observed three types of GNAS mutations
at two sites, R201C (N = 7), R201H (N = 1), and Q227H
(N = 1), all of which are known to activate Gαs [24],
resulting in increased cAMP levels and PKA activity.
The analysis of 14 additional cases indicates that GNAS
was mutated in 82% (19/23) of low-grade MCP or
LAMN and immunostaining of phosphorylated PKA
substrates in 14 low-grade samples reveals strong PKAactivation in all cases (Figures 2 and 3), Finally, both
KRAS and GNAS mutations detected in one low-grade
MCP specimen were also identified in the matched pri-
mary LAMN and associated with the activation of Akt
and PKA (Additional file 1: Figure S3) indicating, for this
patient, the lack of major phenotypic evolution during
the metastasis.
PKA activity in high-grade MCP
The high-grade MCP analyzed by whole exome sequen-
cing differs notably from low-grade MCPs by the larger
number of chromosomal rearrangements, the presence
of a TP53 mutation and the absence of GNAS mutation.
Using ultra deep targeted sequencing in five additional
high-grade MCPs, we were able to detect a GNASmutation
only in one sample, suggesting that the GNAS mutational
status is significantly different between low-grade and high-
grade (21/23 vs. 1/6; P = 0.005; Additional file 3: Table S11
and Figure 2). This observation is consistent with the recent
observation of GNAS mutations in LAMN but not in pri-
mary mucinous adenocarcinoma of the appendix [13]. By
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vation of PKA in 3/3 high-grade MCPs, even in absence of
GNAS mutations (Figures 2 and 3). A close inspection of
the mutations identified in the high-grade MCP sample
from the discovery group revealed a W197S mutation in
the catalytic subunit of PKA (encoded by PRKACA). A dif-
ferent substitution at the same residue is known to result in
PKA constitutive activation [25].
Additional mutated cancer genes
Other cancer genes were recurrently mutated in MNAs.
Members of the TGFβ pathway SMAD2, SMAD3,
SMAD4, TGFBR1, and TGFBR2 were mutated in seven
samples (Figure 2). All mutations are predicted to be
loss of function (Additional file 3: Table S4). Interest-
ingly both SMAD2 mutations identified occur at Ser465
residue, thereby abolishing a phosphorylation site essen-
tial for Smad4 binding and propagation of TGFβ signal-
ing [26]. Furthermore, both SMAD2 mutations are
homozygous due to a loss of heterozygosity of chromo-
some 18 (Additional file 1: Figure S4), suggesting a
complete loss of function. The ultra deep targeted se-
quencing of 19 additional samples reveals deleterious
mutations at Ser464 and Ser467 in two samples
(Additional file 3: Table S11a), suggesting that overall,
Smad2 activity is impaired in approximately 13% of
MNAs. Similarly, both TGFBR1/2 mutations are homo-
zygous and TGFBR1-S241L has been identified in inher-
ited diseases [27,28], suggesting a loss of function.
Therefore, our analysis indicates that 7/10 MNAs may
have impaired TGFβ signaling, a higher incidence than
that observed in non-hypermutated CRC (24%). Genes
in the Hippo pathway were also altered, affecting 4/10
MNAs through mutations in FAT4, FAT3, and DSCH1.
Hippo pathway inactivation has been observed in cancer
[29] including CRC in which both FAT4 and FAT2,
putative Hippo pathway receptors [30], are significantly
mutated in 24% of the cases [15]. FAT4 has been recently
established as a tumor suppressor [31], generally mutated
in less than 10% of epithelial cancers (Additional file 3:
Table S12). Our results therefore suggest that the inacti-
vation of genes in the Hippo pathway may contribute to
MNA development in ways similar to CRC. Genes
belonging to the Wnt pathway were mutated in 3/10
MNAs. Mutations in WNT7A and WNT10A are pre-
dicted to be deleterious (Additional file 3: Table S4)
while CTNNB1-D32N is known to affect the ubiquitina-
tion recognition motif of beta-catenin resulting in in-
creased protein stability [32]. This suggests that Wnt
activation may promote oncogenesis in a subset of MNAs,
despite the notable absence of APC alterations frequently
observed in CRC. Finally, we observed non-synonymous
mutations in other cancer-related genes such as ATR, TP53
(DNA repair), PIK3CA (Akt signaling), c-FOS (Immediateearly oncogene), GRIN2B/2C (Glutamate receptors) or
PKCB/D (PKC subunits). These results, together with
the recurrent mutated gene analysis (Table 1) suggest
that several pathways may contribute to MNA onco-
genesis. Importantly both mutations in DNA repair
pathway genes ATR and TP53 - with loss of heterozy-
gosity - were identified in the high-grade MCP sample
consistent with its higher mutation rate.
MNA molecular relationship to colorectal cancer
Since it was first described in 1842 by Rokitansky, the
site of origin and the underlying pathophysiology of tu-
mors that most commonly give rise to MCP and PMP
have been much debated. The disease classification has
proven difficult owing to the varying histologic appear-
ance and clinical behavior of MNA that metastasize to
the peritoneal surfaces [2]. We present for the first time,
a genome-wide mutational analysis of MCPs of appendiceal
origin, which provides the genetic basis of this unusual dis-
ease. Our analysis reveals some genetic similarities between
MNA and CRC, but many striking differences. Altered in
less than half of CRC, KRAS mutations are present in 90%
of MNAs. Other CRC-related genetic alterations include
frequent amplification at chromosome 1q and loss at the
1q36 locus. This result suggests that MCL1, located on
1q21 and recently reported as amplified in MCP of appen-
diceal origin [33], is part of larger chromosomal gain. Its
oncogenic role in MCP or MNA remains to be established.
Mutations in the Wnt pathway, common in CRC, are also
seen in MNA, but with the remarkable absence of APC
mutations. Similarly, TGFβ is impaired in two cases by the
SMAD2 mutations at Serine 465, never observed in CRC
[34]. Another striking difference between MNA and CRC is
the absence of TP53 mutations, except for a high-grade
sample, consistent with the association of high-grade hist-
ology with increased chromosomal instability. In comple-
ment to our study, we also ordered the clinical sequencing
of a 236-genes panel (Foundation One - Foundation Medi-
cine, Cambridge, MA, USA) for seven additional patients
diagnosed with high-grade MCP. The test includes genes
such as APC, TP53, KRAS, GNAS, CTNNB1, TGFBR2,
SMAD2, SMAD4, and PKAR1A. While no mutations were
reported in APC, SMAD2, CTNNB1, or PKAR1A, the
majority of patients carried mutations in KRAS (N = 4),
GNAS (N = 1), TP53 (N = 3), TGFBR2 (N = 1), and
SMAD4 (N = 1), thus showing consistency with our ini-
tial findings. One explanation for the lower fraction of
KRAS-mutated samples is the greater sensitivity of our
research assay, involving laser capture microdissection,
inclusion of a matched germline control and analytical
optimization for low cellularity specimen. Owing to the
rarity of MNA and the technical challenges with tissue
collection and sample preparation, our study was con-
ducted with a relatively limited number of samples and
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to determine the potential role TGFβ and Wnt signaling
pathways in appendiceal tumorigenesis.
Perspective on Ras and PKA pathway crosstalk
In contrast to a previous report which lacked sensitivity
and did not assess downstream pathway activity [13],
our work formally establishes the universal activation of
the PKA pathway in most MNAs, most often through
activating mutations in GNAS. We observed that activat-
ing mutations in GNAS and KRAS co-exist in neoplasms
at high frequency only in MNAs and pancreatic IPMN
(Figure 4a). Interestingly, both IPMN and low-grade
MNA are benign tumors that share important common
clinico-pathologic characteristics such as slow-growth,
invasiveness, and high production of mucin. In addition,
when clinically localized to the organ of origin, they each
have a favorable prognosis when treated with surgical
resection. It is possible that the common clinico-
pathological features are the direct consequence of the
simultaneous activation of KRAS and GNAS within two
major signaling pathways (Ras-PI3K-Akt and cAMP-PKA).
The activation of these two pathways can be symbiotic and
sustain cell growth (Figure 4b). Indeed, although KRAS-
mutated cells are susceptible to apoptosis in low-glucoseFigure 4 Frequent and complex interplay between KRAS and GNAS in
is uncommon in neoplastic lesions. Bar graphs represent the frequency of
neoplasms reported in COSMIC (v63 database) or in IPMN [22] or MNA (this stu
Simplified representation of the cross-talk between Ras and PKA pathway and t
KRAS and GNAS can coordinately deregulate multiple oncogenic signalin
and progression of MNAs. Symbiotic (dark blue), synergistic (light blue),
and KRAS oncogenes, and possibly members of the TGFβ-SMAD pathwacondition, this effect can be countered by high cAMP
levels, increasing proliferation [35]. In addition, GNAS-mu-
tated cells may not have proliferative advantage over nor-
mal cells [36] but are predicted to be more invasive by
triggering regulated exocytosis of multiple MMPs, VEGF
and mucins [37-40] and transcriptional upregulation of
MUC1 oncogene [41]. Thus, this suggests that each muta-
tion depends on the other to gain some advantageous
phenotype, balancing proliferation, and invasive capacity.
Additional interactions in the two pathways may explain
the relatively indolent course observed in both MNA and
IPMN. Indeed the Ras-PI3K-Akt pathway activates PDE4B,
a potent scavenger of cAMP [42], thus mitigating the effect
of GNASmutations located upstream in the pathway. Inter-
estingly, we found that a high-grade MCP lacking GNAS
mutations carries instead an activating mutation in PKA.
Such tumors would be insensitive to Ras-PI3K-Akt medi-
ated activation of PDE4B and degradation of cAMP. This
effect would allow the synergy between RAS and cAMP
pathways to impart a higher-grade histology. Furthermore,
cAMP is known to inhibit Ras-Raf-Erk signaling [43]. This
antagonism can be observed in our IHC experiment
(Figure 2) where 11/19 and 19/19 MNAs display activated
Erk and Akt, respectively, suggesting that the Ras- PI3K-
Akt pathway is more consistently activated than the Ras-MNAs. (a) High frequency of co-existing KRAS and GNAS mutations
activating mutations in KRAS and GNAS oncogenes among various
dy). Only tissues with more than 10 evaluated samples are reported. (b)
he likely impact on MNA progression. Co-existing activating mutations in
g pathways (Wnt, hedgehog, and TGFβ-SMAD) triggering initiation
and antagonistic (dark red) signals triggered by mutations in GNAS
y may all contribute to the metastatic progression of MNA.
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talk between the two pathways, both synergetic and antag-
onistic (Figure 4b), suggesting areas of future investigation
to determine their importance in MNA etiology. The ab-
sence of recurrent GNAS mutations in high-grade tumors
also suggests that, in most cases, they do not progress from
a low-grade lesion. The only high grade MCP case also mu-
tated for GNAS showed additional low-grade lesions in dif-
ferent areas of the peritoneal cavity. The specimen studied
may have contained a portion of low grade MCP not seen
in the diagnostic section, or alternatively, both types of le-
sions may have a putative common origin in this patient.
The presence of KRAS alterations in both high-grade and
low-grade tumors suggests that the KRAS mutation occurs
earlier in the course of tumorigenesis. Finally, lesions ac-
quiring GNAS mutations seem to ultimately result in low-
grade tumors, while activation of the PKA signaling via
alternative mechanisms, accompanied by additional muta-
tions such as TP53, seems to be characteristic of high-grade
tumors.
Clinical implications
GNAS mutations have also been recently reported in
precancerous/benign lesions of the digestive tract: villous
adenomas in the stomach and in the colon [20,23].
Interestingly, villous architecture and high mucin secre-
tion are a common characteristic of these tumor types.
The malignant potential of villous adenomas of the ap-
pendix is well-documented and it is estimated that ap-
proximately 40% to 66% of non-invasive adenomas may
eventually transform into carcinoma in situ [44]. Thus,
it is tempting to speculate that MNAs may originate
from villous adenomas of the appendix. In contrast to
colorectal villous adenomas, mucin generated by MNA
would accumulate locally in the small lumen of the ap-
pendix, leading to rupture into the peritoneal cavity and
increased risk of MCP.
Our findings also have some immediate implications
for the management of patients with MCP secondary to
MNA that is not amenable to surgical cytoreduction.
KRAS testing done via CLIA approved methods has
yielded mutation rates in the range of 50% to 60%, con-
siderably lower than what we observed in this study. It is
not surprising that current diagnostic assays underesti-
mate the incidence of KRAS mutations given the hypo-
cellular nature of metastatic lesions from MCP. False
negative results have profound clinical implications as
many MNA patients are subject to therapy with EGFR
monoclonal antibodies which are ineffective and poten-
tially harmful in the presence of mutant KRAS. Our
findings also raise the potential for novel targeted ap-
proaches to MNA. The universal presence of oncogenic
KRAS mutations leading to phosphorylation of Erk, as
well as the fact that MEK-ERK signaling can activatetranscription of MUC2, suggests that MEK inhibitors
would be logical agents to explore in this disease. Simi-
larly, given the consistent activation of Akt in MNA,
targeting PI3K/AKT signaling may also have clinical
benefits [45]. Agents targeting the cAMP-PKA pathway
would also be sensible choices given the deregulation of
this pathway in nearly all samples. Given that the pro-
duction and secretion of mucin accounts for much of
the morbidity from this tumor type, even therapies that
act solely to reduce mucin production and secretion
alone could have profound clinical value. Finally, agents
targeting TGFβ and Wnt signaling may provide thera-
peutic opportunities in selected cases. The current lack
of suitable preclinical models of MNA make proof of
concept studies challenging, but the information gained
here may guide development of such models and en-
courage further research on MNAs.Conclusions
The genome-wide mutational analysis of mucinous carcin-
omatosis peritonei of appendiceal origin reveals genetic
alterations distinct from colorectal cancer. Mutations in
both Ras and PKA pathways, which are tightly interacting,
are consistent with the unique pathophysiology of the dis-
ease: a slow progressing neoplasm accompanied by import-
ant secretion of mucin. Additionally, the lower prevalence
of GNAS mutations in high-grade lesions indicates that
they do not progress from low-grade. Finally, the very fre-
quent activation of Ras and PKA pathways, as well as spor-
adic alterations in TGFβ and Wnt signaling pathways
suggest, for the first time, that targeted therapies may have
important benefits for these patients, which are currently
primarily treated with surgery and chemotherapy.Additional files
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